ImageneBio IMA
NASDAQ IMA
$5.61 +0.10 (+1.81%)
At close: Aug 20, 2026 · 4:00 PM EDT

ImageneBio (IMA) Short term Debt (2024)

ImageneBio (IMA) posted Short term Debt of $7.5 million for Q4 2024.

ImageneBio (IMA) Short term Debt (2024) Analysis & Trends

ImageneBio has reported Short term Debt for 1 years, with the latest figure at $7.5 million in Q4 2024.

  • Quarterly Short term Debt changed N/A year-over-year to $7.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7.5 million (changed N/A YoY) and the FY2024 annual result came in at $7.5 million, changed N/A from the prior year.
  • Short term Debt was little changed at $7.5 million in Q4 2024 per IMA's latest filing.
  • Over five years, Short term Debt peaked at $7.5 million in Q4 2024 and troughed at $7.5 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 ImageneBio 48.60 Mn -86.75 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 7.50 Mn